Wave Life Sciences Past Earnings Performance

Past criteria checks 0/6

Wave Life Sciences has been growing earnings at an average annual rate of 15%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 40.2% per year.

Key information

15.0%

Earnings growth rate

40.4%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate40.2%
Return on equity-95.3%
Net Margin-265.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Wave Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:1U5 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2454-143570
30 Jun 24111-73550
31 Mar 24113-62530
31 Dec 23113-58510
30 Sep 2385-85510
30 Jun 2337-131500
31 Mar 2315-151500
31 Dec 224-162510
30 Sep 224-153490
30 Jun 2240-120500
31 Mar 2243-118480
31 Dec 2141-122460
30 Sep 2149-116440
30 Jun 2116-143400
31 Mar 2116-145400
31 Dec 2020-150430
30 Sep 2013-178470
30 Jun 2013-196500
31 Mar 2017-197510
31 Dec 1916-194490
30 Sep 1917-175480
30 Jun 1919-162450
31 Mar 1916-156420
31 Dec 1814-147400
30 Sep 1812-140340
30 Jun 189-127310
31 Mar 185-116290
31 Dec 174-102270
30 Sep 173-90250
30 Jun 173-82220
31 Mar 172-69190
31 Dec 161-56160
30 Sep 161-44150
30 Jun 160-31130
31 Mar 160-24120
31 Dec 150-19100
30 Sep 150-1480
30 Jun 150-1060
31 Mar 150-840

Quality Earnings: 1U5 is currently unprofitable.

Growing Profit Margin: 1U5 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 1U5 is unprofitable, but has reduced losses over the past 5 years at a rate of 15% per year.

Accelerating Growth: Unable to compare 1U5's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1U5 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.4%).


Return on Equity

High ROE: 1U5 has a negative Return on Equity (-95.32%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 10:25
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Wave Life Sciences Ltd. is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madison Wynne El-SaadiB. Riley Securities, Inc.
Steven SeedhouseCGS International
Whitney IjemGuggenheim Securities, LLC